# US 2015/0148322 A1 · Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0148322 A1
- Document ID: US20150148322A1
- Status: Published application
- Kind: A1
- Application number: 14/239,818
- Filed: 2012-03-15
- Published: 2015-05-28
- Earliest claimed: 2011-08-24
- Assignees: Boehringer Ingelheim International GmbH
- Inventors: Pascale A.J. Pouzet; Peter Nickolaus; Ulrike Werthmann; Rogelio P. Frutos; Bing-Shiou Yang; Soojin Kim; Jason Alan Mulder; Nitinchandra Patel; Chris H. Senanayake; Thomas G. Tampone; Xudong Wei
- Web page: https://patentgrep.com/patent/US20150148322A1

## CPC

- C07D 495/04: Ortho-condensed systems
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/04: for throat disorders
- A61P 11/06: Antiasthmatics
- A61P 11/08: Bronchodilators
- A61P 11/12: Mucolytics
- A61P 11/16: Central respiratory analeptics
- A61P 17/00: Drugs for dermatological disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 27/04: Artificial tears; Irrigation solutions
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 213/00: Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The invention relates to novel piperidino-dihydrothienopyrimidine sulfoxides of formula I, wherein Ring A is a 6-membered aromatic ring which may optionally comprise one or two nitrogen atoms and wherein R is Cl and wherein R may be located either in the para-, meta- or ortho-position of Ring A, wherein S* is a sulphur atom that represents a chiral center, and all pharmaceutically acceptable salts, enantiomers and racemates, hydrates and solvates thereof and the use of these compounds for the treatment of inflammatory or allergic diseases of the respiratory tract such as COPD or asthma.

## Claims

### Claim 1

The compound of formula I
wherein:
Ring A is a 6-membered aromatic ring optionally comprising one or two nitrogen atoms;
R is Cl;
R is located in the para-, meta-, or ortho-position of Ring A; and
S* is a sulphur atom that represents a chiral center,
or a pharmaceutically acceptable salts thereof.

### Claim 2 (depends on 1)

The compound of formula I according to claim 1, wherein R is Cl and wherein R is located in the para-position of Ring A, or a pharmaceutically acceptable salts thereof.

### Claim 3 (depends on 1)

The compound of formula I according to claim 1, wherein Ring A is phenyl, pyridinyl, or and pyrimidinyl, or a pharmaceutically acceptable salts thereof.

### Claim 4 (depends on 1)

The compound according to claim 1, wherein the compound is a compound of formula H
or a pharmaceutically acceptable salts thereof.

### Claim 5 (depends on 1)

The compound according to claim 1, the compound is a compound of formula III
or a pharmaceutically acceptable salts thereof.

### Claim 6 (depends on 1)

The compound according to claim 1, wherein S* is a sulphur atom in the R-configuration.

### Claim 7 (depends on 1)

The compound according to claim 1, wherein S* is a sulphur atom in the S-configuration.

### Claim 8 (depends on 5)

A crystalline anhydrous compound of formula III according to claim 5, which shows a reflex peak in the X-ray powder diffraction diagram with a d-value of 4.62 Å.

### Claim 9 (depends on 5)

A crystalline anhydrous compound of formula III according to claim 5, which shows reflex peaks in the X-ray powder diffraction diagram with d-values of 4.62 Å, 6.82 Å and 10.09 Å.

### Claim 10 (depends on 5)

A crystalline anhydrous compound of formula III according to claim 5, which shows reflex peaks in the X-ray powder diffraction diagram with d-values of 4.62 Å, 4.17 Å and 3.66 Å.

### Claim 11 (depends on 5)

A crystalline anhydrous compound of formula III according to claim 5, which shows reflex peaks in the X-ray powder diffraction diagram with d-values of 4.62 Å, 6.82 Å, 10.09 Å, 3.93 Å and 4.94 Å.

### Claim 12 (depends on 5)

A crystalline anhydrous compound of formula III according to claim 5, which shows reflex peaks in the X-ray powder diffraction diagram with d-values of 4.62 Å, 4.17 Å, 3.66 Å, 3.73 Å and 18.47 Å.

### Claim 13 (depends on 5)

A crystalline dihydrate compound of formula III according to claim 5, which shows a reflex peak in the X-ray powder diffraction diagram with a d-value of 4.12 Å.

### Claim 14 (depends on 5)

A crystalline dihydrate compound of formula III according to claim 5, which shows reflex peaks in the X-ray powder diffraction diagram with d-values of 4.12 Å, 4.29 Å and 5.15 Å.

### Claim 15 (depends on 5)

A crystalline dihydrate compound of formula III according to claim 5, which shows reflex peaks in the X-ray powder diffraction diagram with d-values of 4.12 Å, 4.29 Å, 5.15 Å, 3.95 Å and 3.36 Å.

### Claim 16

(canceled)

### Claim 17 (depends on 1)

A method of treating a disease which can be treated by the inhibition of the PDE4-enzyme in a patient in need thereof, the method comprising administering to the patient an effective amount of the compound according to claim 1.

### Claim 18 (depends on 17)

The method according to claim 17, wherein the disease that can be treated by the inhibition of the PDE4-enzyme is selected from a respiratory disease, a gastrointestinal disease, an inflammatory disease of the joints, the skin, or the eyes, cancer, and a disease of the peripheral or central nervous system.

### Claim 19 (depends on 18)

The method according to claim 18, wherein the disease that can be treated by the inhibition of the PDE4-enzyme is selected from a respiratory or pulmonary disease which is accompanied by increased mucus production, inflammations, and/or obstructive diseases of the respiratory tract.

### Claim 20 (depends on 19)

The method according to use of claim 19, wherein the disease that can be treated by the inhibition of the PDE4-enzyme is selected from COPD, idiopathic pulmonary fibrosis, alpha 1 antitrypsin deficiency, chronic sinusitis, asthma, and chronic bronchitis.

### Claim 21 (depends on 17)

The method according to use of claim 17, wherein the disease that can be treated by the inhibition of the PDE4-enzyme is an inflammatory disease of the joints, the skin or the eyes selected from the group consisting of rheumatoid arthritis, sarcoidosis, dry eyes syndrome, and glaucoma.

### Claim 22 (depends on 17)

The method according to claim 17, wherein the disease that can be treated by the inhibition of the PDE4-enzyme is selected from Crohn's disease or ulcerative colitis.

### Claim 23 (depends on 17)

The method according to of claim 17, wherein the disease that can be treated by the inhibition of the PDE4-enzyme is selected from depression, bipolar or manic depression, acute and chronic anxiety states, schizophrenia, Alzheimer's disease, Parkinson's disease, acute and chronic multiple sclerosis or acute and chronic pain and brain damage caused by stroke, hypoxia or cranio-cerebral trauma, dry eyes syndrome, and glaucoma.

### Claim 24 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1 and an excipient.

### Claim 25 (depends on 1)

A pharmaceutical composition according to claim 1 and an active substance selected from the group consisting of betamimetics, corticosteroids, anticholinergics, other PDE4 inhibitors, NSAIDS, COX2-inhibitors, EP4-receptor antagonists, EGFR-inhibitors, LTD4-antagonists, CCR3-inhibitors, iNOS-inhibitors, MRP4-inhibitors, and SYK inhibitors.

### Claim 26

A method of making the compound A
wherein HX is a pharmaceutically acceptable acid, the method comprising:
a) reducing compound B
wherein HY is a pharmaceutically acceptable acid,
with borane; and
b) adding a pharmaceutically acceptable acid HX to obtain compound A.

### Claim 27 (depends on 6)

The method of claim 6, wherein the borane is added directly.

### Claim 28 (depends on 6)

The method of claim 6, wherein the borane is generated in-situ.

### Claim 29 (depends on 28)

The method of claim 28, wherein the borane is generated either from the combination of NaBH4 and I2 or from the combination of NaBH4 and BF3—OEt2.

### Claim 30

The method of 26, wherein HX is tosylic acid or hydrochloric acid.

### Claim 31 (depends on 25, 26)

The method of claims 25 to 26, wherein the pharmaceutically acceptable acid HY in compound B is HCl.

### Claim 32

A method of making compound C
wherein HX is tosylic acid, hydrochloric acid, or sulphuric acid, the method comprising:
A) first contacting 4-cyano-piperidine with an acid and then reacting with ammonia in order to obtain intermediate E
B) reacting intermediate E is with compound D in the presence of a base
and
C) adding the acid HX to obtain compound C.

### Claim 33 (depends on 31)

The method of claim 31, wherein the acid in step A) is hydrochloric acid.

### Claim 34 (depends on 31)

The method of claim 31, wherein the base in step B) is sodium methanolate.

### Claim 35

The intermediate compound of formula VIII
or a salt thereof.

### Claim 36

The intermediate compound of formula IX
wherein S* is a sulphur atom that represents a chiral center,
or a salts thereof.
